Synapse

← Gordon B. Mills

Papers by Gordon B. Mills

Page 5 · newest first

  1. Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines2020
  2. Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathwaysProceedings of the National Academy of Sciences · 2020
  3. Frequent post-treatment monitoring of colorectal cancer using individualized ctDNA validated by multi-regional molecular profiling2020
  4. BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-AnalysisJNCI Journal of the National Cancer Institute · 2020
  5. p85β regulates autophagic degradation of AXL to activate oncogenic signalingNature Communications · 2020
  6. Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasisMolecular Oncology · 2020
  7. Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma TumorsCancers · 2020
  8. Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein ArraysJCO Clinical Cancer Informatics · 2020
  9. Sex-associated molecular differences for cancer immunotherapyNature Communications · 2020
  10. Acquired Uniparental Disomy Regions Are Associated with Disease Outcome in Patients with Oral Cavity and Oropharynx But Not Larynx CancersTranslational Oncology · 2020
  11. Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progressioneLife · 2020
  12. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor EfficacyCancer Immunology Research · 2020
  13. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology TrialsJournal of the National Comprehensive Cancer Network · 2020
  14. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian CancerCell Reports · 2020
  15. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsClinical Cancer Research · 2020
  16. Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin–Stained Sections of Core-Needle Biopsy SpecimensJAMA Network Open · 2020
  17. Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patientsExpert Review of Proteomics · 2020
  18. Immuno-genomic landscape of osteosarcomaSHILAP Revista de lepidopterología · 2020
  19. Comprehensive assessment of computational algorithms in predicting cancer driver mutationsGenome biology · 2020
  20. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinomaBritish Journal of Cancer · 2020
  21. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)Gynecologic Oncology Reports · 2020
  22. Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1npj Breast Cancer · 2020
  23. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBCTheranostics · 2020
  24. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast CancerCell Reports · 2019
  25. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancersBritish Journal of Cancer · 2019
  26. Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancerInternational Journal of Cancer · 2019
  27. A-to-I–edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosisJournal of Clinical Investigation · 2019
  28. Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell CarcinomaNeoplasia · 2019
  29. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancerNature Communications · 2019
  30. Proteomics advances for precision therapy in ovarian cancerExpert Review of Proteomics · 2019
  31. Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell linesGenome Medicine · 2019
  32. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic ReprogrammingCell Reports · 2019
  33. The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progressionnpj Breast Cancer · 2019
  34. Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer2019
  35. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent MechanismsClinical Cancer Research · 2019
  36. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationBreast Cancer Research · 2019
  37. A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell LinesCell Systems · 2019
  38. TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic DataMolecular & Cellular Proteomics · 2019
  39. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy optionsOncotarget · 2019
  40. Expanded Analysis of Secondary Germline Findings From Matched Tumor/Normal Sequencing Identifies Additional Clinically Significant MutationsJCO Precision Oncology · 2019
  41. Breast cancer quantitative proteome and proteogenomic landscapeNature Communications · 2019
  42. Prospective Clinical Sequencing of Adult GliomaMolecular Cancer Therapeutics · 2019
  43. Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activityPLoS ONE · 2019
  44. Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumorsOncotarget · 2019
  45. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special ConferenceCancer · 2019
  46. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor modelsScientific Reports · 2019
  47. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancerNature Communications · 2019
  48. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumAnnals of Oncology · 2019
  49. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast CancerMolecular Cancer Therapeutics · 2019
  50. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancerThe Journal of Experimental Medicine · 2019